Wearable monitoring compared with usual checks for hospitalized heart and blood vessel patients
Tests a wireless wearable monitor against usual checks in hospitalized adults with heart disease.
Key facts
- Who runs it
- Yonsei University
- Where
- Yongin, South KoreaSee the site
- Trial code
- Registry title
- In-Hospital Wearable-Based Monitoring Versus Standard Care in Cardiovascular Disease (INSPIRE)
- Status
- Not yet recruiting
- People taking part
- 1,500 people, planned
- Started
- 1 Jul 2026
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- thynC Inpatient Monitoring System
- Record updated
- 3 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in hospital with heart or blood vessel disease. It tests wearable continuous monitoring against standard checks.
- Age
- 20 years or older
- Sex
- All sexes can join.
- Disease stage
- Hospitalized for cardiovascular disease: acute or chronic coronary syndrome, acute heart failure (NYHA class III-IV or acute decompensated), significant arrhythmia, peripheral arterial or aortic disease, observation after a heart procedure, or thromboembolic disease.
Main reasons for not taking part
- Unstable shock needing vasopressors, including cardiogenic or septic shock
- Planned or current intensive care unit admission
- Within 24 hours after cardiopulmonary resuscitation
- Cannot wear the device (for example severe skin lesion or burn at the device site, or allergy to device materials)
- ECMO or intra-aortic balloon pump in use
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Adults aged 20 years or older
- Hospitalized for cardiovascular disease, with at least one of: acute coronary syndrome; chronic coronary syndrome; acute heart failure (NYHA class III-IV or acute decompensated heart failure); arrhythmia (atrial fibrillation, ventricular tachycardia, complete AV block, or other clinically significant arrhythmia); peripheral arterial or aortic disease; post-cardiovascular-procedure observation (PCI, CABG, valve surgery, or electrophysiology study); or thromboembolic disease
- Able to provide written informed consent
- Able to wear the wearable monitoring device
Who cannot take part
- Continuous renal replacement therapy (CRRT) in use (patients on CRRT may participate if hemodynamically stable and device wearing is technically feasible)
- Previously enrolled in this study (re-admitted patients are not re-enrolled; each participant is enrolled only at the first admission)
- Physical condition precluding device wearing (bilateral upper-limb amputation; severe skin lesion, burn, or open wound at the device site; known allergy to device materials)
- Severe cognitive impairment or delirium precluding informed consent Extracorporeal membrane oxygenation (ECMO) or intra-aortic balloon pump (IABP) in use
- Hemodynamically unstable shock (sustained systolic blood pressure < 90 mmHg requiring vasopressors; cardiogenic shock; septic shock)
- Planned or current intensive care unit admission
- Within 24 hours after cardiopulmonary resuscitation
- Unable to communicate in Korean for study explanation and the consent process
- Considered inappropriate for participation by the investigator
Where in South Korea
- Yonsei University Yongin Severance HospitalYongin, South KoreaContact: Deok-Kyu Cho, MD.Not yet recruiting
About the trial
What the trial wants to find out
Patients hospitalized with cardiovascular disease require timely detection of clinical deterioration to prevent adverse outcomes. Standard inpatient care relies on intermittent nursing vital-sign measurements performed every 4 to 8 hours, which can miss hemodynamic or arrhythmic events occurring between measurements. This trial evaluates whether digital wearable-based monitoring - wireless continuous measurement of vital signs and electrocardiography with a real-time alerting system - reduces major adverse cardiovascular events (MACE) compared with standard intermittent monitoring in patients hospitalized for cardiovascular disease. The trial uses a stepped-wedge cluster-randomized design in which four inpatient ward zones (clusters) are sequentially transitioned from standard care to wearable monitoring over five periods.
The 2 groups in the trial
- Wearable-based monitoring (intervention)Treatment being tested
During periods in which the patient's cluster operates in the intervention state, patients receive continuous wearable monitoring using the thynC Inpatient Monitoring System with a real-time alerting system, in addition to standard care.
Treatment: thynC Inpatient Monitoring System
- Standard care (control)No study treatment, for comparison
During periods in which the patient's cluster operates in the control state, patients receive standard care, including intermittent nursing vital-sign measurement every 4 to 8 hours.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- In-Hospital Efficacy and Safety of Wearable-Based Monitoring Versus Standard Care in Cardiovascular Disease: A Stepped-Wedge Cluster Randomized Controlled Trial (INSPIRE Trial)
- Plain-language title
- Wearable monitoring compared with usual checks for hospitalized heart and blood vessel patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 3 June 2026